Acquisition leverage Certara’s acquisition of Applied BioMath indicates a strategic move to broaden biosimulation capabilities. This suggests cross-selling opportunities with Certara’s existing pharma and biotech clients and potential integration pathways to offer enhanced MID3 services within a larger portfolio.

Mid-market focus Applied BioMath operates with 11-50 employees and reported revenue in the 1–10 million range. Target mid-market biotech and early-to-mid stage biopharma companies seeking risk reduction in R&D through model-informed drug discovery and development (MIDI3) represents a strong sales segment.

Proven collaborations Longstanding partnerships with Celsius Therapeutics and Monte Rosa Therapeutics, plus ongoing university and industry collaborations, demonstrate credibility and a ready-made reference base. This can be leveraged to pitch joint development or expanded modeling services to similar firms pursuing systems pharmacology and mechanistic modeling.

Therapeutic focus Active work on immunocytokines, monoclonal antibodies, inflammatory bowel disease models, and cereblon-based degraders indicates specialization in oncology and immunology. Sales outreach can target biotechs and CROs focused on these modalities with a modular MID3 offering for dose optimization and therapeutic window prediction.

Global decision support The company highlights global decision-making support across R&D stages via MADI and high-performance computing. This presents a selling point for multinational programs, asking for scalable, platform-backed modeling solutions that can harmonize data and provide consistent dosing and development strategies across sites.